Enterprise Value
489.8M
Cash
120.1M
Avg Qtr Burn
-7.238M
Short % of Float
16.81%
Insider Ownership
0.87%
Institutional Own.
93.39%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CRB-701 (Nectin-4 ADC) Details Solid tumor/s, Urothelial cancer, Cancer | Phase 1 Update | |
CRB-601 (anti-αvβ8) Details Solid tumor/s | Phase 1 Initiation | |
Lenabasum Details Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease | Failed Discontinued | |
Lenabasum Details Cystic fibrosis | Failed Discontinued | |
Lenabasum Details Systemic sclerosis | Failed Discontinued | |
Lenabasum (JBT-101) Details Autoimmune disease | Failed Discontinued |